Yarrow Bioscience (YARW) Retained Earnings (2016 - 2026)
Yarrow Bioscience's (YARW) quarterly Retained Earnings came in at -$757.7 million in Q4 2025, down 3788365.0% YoY from N/an in Q4 2024, and down 196.59% on a QoQ basis from $784.4 million in Q2 2025.
Yarrow Bioscience (YARW) Retained Earnings (2016 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 10 years of Retained Earnings data on file, last reported at -$757.7 million in Q4 2025.
- Quarterly Retained Earnings fell 3788365.0% year-over-year to -$757.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$757.7 million (down 3788365.0% YoY) and the FY2025 annual result came in at -$757.7 million, down 3788365.0% from the prior year.
- Retained Earnings fell to -$757.7 million in Q4 2025, from $784.4 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $784.4 million in Q2 2025 to a low of -$757.7 million in Q4 2025.
- A 5-year average of -$45.2 million and a median of -$293.4 million in 2021 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2021 — Retained Earnings soared 226.49% — and 2025, when it tumbled 3788365.0%.
- Tracing YARW's Retained Earnings over 5 years: stood at $688.2 million in 2021, then sank by 194.86% to -$652.8 million in 2022, then jumped by 100.0% to $26000.0 in 2023, then retreated by 23.08% to $20000.0 in 2024, then plunged by 3788365.0% to -$757.7 million in 2025.
- The last three Retained Earnings figures came in at -$757.7 million (Q4 2025), $784.4 million (Q2 2025), and -$739.8 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - | 786.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 786.31 Mn |
| Mar 31, 2026 | 785.87 Mn |
| Dec 31, 2025 | -757.65 Mn |
| Jun 30, 2025 | 784.42 Mn |
| Mar 31, 2025 | -739.78 Mn |
| Dec 31, 2024 | 20,000.00 |
| Sep 30, 2024 | 782.65 Mn |
| Jun 30, 2024 | 781.92 Mn |
| Mar 31, 2024 | 781.02 Mn |
| Dec 31, 2023 | 26,000.00 |
| Sep 30, 2023 | -685.15 Mn |
| Jun 30, 2023 | -678.56 Mn |
| Mar 31, 2023 | -668.51 Mn |
| Sep 30, 2022 | -652.80 Mn |
| Jun 30, 2022 | 691.68 Mn |
| Mar 31, 2022 | -634.90 Mn |
| Dec 31, 2021 | 688.16 Mn |
| Sep 30, 2021 | 686.84 Mn |
| Jun 30, 2021 | -606.67 Mn |
| Mar 31, 2021 | -586.75 Mn |